Home › Research › Drug development
Enhancing autophagy in Alzheimer's disease through drug repositioning
Mehdi Eshraghi, Mazaher Ahmadi, Saeid Afshar, Shahrokh Lorzadeh, Aida Adlimoghaddam, Nahid Rezvani Jalal, Ryan West, Sanaz Dastghaib et al.. Pharmacology & therapeutics, 2022-03-16
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
Alzheimer's disease (AD) is one of the biggest human health threats due to increases in aging of the global population. Unfortunately, drugs for treating AD have been largely ineffective. Interestingly, downregulation of macroautophagy (autophagy) plays an essential role in AD pathogenesis. Therefore, targeting autophagy has drawn considerable attention as a therapeutic approach for the treatment of AD. However, developing new therapeutics is time-consuming and requires huge investments. One of the strategies currently under consideration for many diseases is "drug repositioning" or "drug repurposing". In this comprehensive review, we have provided an overview of the impact of autophagy on AD pathophysiology, reviewed the therapeutics that upregulate autophagy and are currently used in the treatment of other diseases, including cancers, and evaluated their repurposing as a possible treatment option for AD. In addition, we discussed the potential of applying nano-drug delivery to neurodegenerative diseases, such as AD, to overcome the challenge of crossing the blood brain barrier and specifically target molecules/pathways of interest with minimal side effects.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Jalal, N. R., et al. (2022). Enhancing autophagy in Alzheimer's disease through drug repositioning. Pharmacology & therapeutics. https://doi.org/10.1016/j.pharmthera.2022.108171
Vancouver
Eshraghi M, Ahmadi M, Afshar S, Lorzadeh S, Adlimoghaddam A, Jalal NR, et al. Enhancing autophagy in Alzheimer's disease through drug repositioning. Pharmacology & therapeutics. 2022. doi:10.1016/j.pharmthera.2022.108171. PMID: 35304223.
BibTeX
@article{eshraghi2022-35304223,
author = {Eshraghi, Mehdi and Ahmadi, Mazaher and Afshar, Saeid and Lorzadeh, Shahrokh and Adlimoghaddam, Aida and Jalal, Nahid Rezvani and West, Ryan and Dastghaib, Sanaz and others},
title = {{Enhancing autophagy in Alzheimer's disease through drug repositioning}},
journal = {Pharmacology \& therapeutics},
year = {2022},
doi = {10.1016/j.pharmthera.2022.108171},
pmid = {35304223},
url = {https://doi.org/10.1016/j.pharmthera.2022.108171}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Therefore, targeting autophagy has drawn considerable attention as a therapeutic approach for the treatment of AD.
- However, developing new therapeutics is time-consuming and requires huge investments.
- One of the strategies currently under consideration for many diseases is "drug repositioning" or "drug repurposing".
- In this comprehensive review, we have provided an overview of the impact of autophagy on AD pathophysiology, reviewed the therapeutics that upregulate autophagy and are currently used in the treatment of other diseases, including cancers, and evaluated their repurposing as a possible treatment option for AD.
- In addition, we discussed the potential of applying nano-drug delivery to neurodegenerative diseases, such as AD, to overcome the challenge of crossing the blood brain barrier and specifically target molecules/pathways of interest with minimal side effects.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 23 of the 56 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pharmacology & therapeutics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35304223) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 23 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 23 of the 56 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “proteostasis”
241 studies in the library carry the topic tag “proteostasis”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 241 tagged studies.